For research use only. Not for therapeutic Use.
M1002 is a hypoxia-inducible factor-2 (HIF-2) agonist, and can enhance the expression of HIF-2 target genes. M1002 shows synergy with prolyl-hydroxylase domain (PHD) inhibitors[1].
M1002 (10 μM; 24 h) enhances the expression of HIF-2 target genes with great efficacy[1].
M1002 (5 μM; 24 h) treatment shows synergy with prolyl hydroxylase domain (PHD) inhibitors[1].
| Catalog Number | I031348 |
| CAS Number | 823830-85-9 |
| Synonyms | N-[3,5-bis(trifluoromethyl)phenyl]-1,1-dioxo-1,2-benzothiazol-3-amine |
| Molecular Formula | C15H8F6N2O2S |
| Purity | ≥95% |
| InChI | InChI=1S/C15H8F6N2O2S/c16-14(17,18)8-5-9(15(19,20)21)7-10(6-8)22-13-11-3-1-2-4-12(11)26(24,25)23-13/h1-7H,(H,22,23) |
| InChIKey | BMTRZTPPTZHACH-UHFFFAOYSA-N |
| SMILES | C1=CC=C2C(=C1)C(=NS2(=O)=O)NC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F |
| Reference | [1]. Dalei Wu, et al. Bidirectional modulation of HIF-2 activity through chemical ligands. Nat Chem Biol. 2019 Apr;15(4):367-376. |
